Presence of Particulate Matter: Discolored solution due to a chip in the glass at the neck of the vial, also glass particulate was found within the solution.
Take action
Contact the company
📍Recalling firmHospira Inc.375 N Field Dr · Lake Forest, IL 60045-2513
✎ GovInfoNow plain-language explainer
Hospira Inc. is recalling 123,900 vials of Dobutamine Injection, USP (250 mg per 20 mL) due to the presence of particulate matter. The hazard involves a chip in the glass neck of the vial that can cause solution discoloration and release glass particles into the medication. This recall affects units distributed nationwide and in Puerto Rico. Read more at govinfonow.com/recall/46321-hospira-inc-recalls-dobutamine-injection-usp-250-mg-per-20.
“Hospira Dobutamine Recall: Glass Particulate Hazard.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/46321-hospira-inc-recalls-dobutamine-injection-usp-250-mg-per-20. Based on FDA recall #D-1540-2014 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1540-2014%22&limit=1).
The FDA announced on Jan. 10, 2014, that Hospira Inc. voluntarily recalled DOBUTamine Injection vials due to glass particulate matter in the solution. Owners should return the product for a refund.
How to tell if you have it
Brand: Hospira
Product: DOBUTamine Injection, USP, 250 mg per 20 mL, 20 mL Single-dose Fliptop Vial
NDC: 0409-2344-02
Lot #: 27-352-DK
Expiration: 03/15
Quantity: 123,900 vials
The hazard
The recall addresses the presence of particulate matter, specifically a discolored solution caused by a chip in the glass at the neck of the vial and glass particulate found within the solution.
Context
GovInfoNow's records show Hospira Inc. has had 108 other recalls on record since April 5, 2012. Other recent recalls of similar products include Sun Pharmaceutical DOXOrubin Liposome Injection (May 12, 2026), American Regent Papaverine HCl Injection (July 24, 2026), and Fresenius Kabi Tyenne Injection (Aug. 10, 2026).
How to tell if you have this one
Check for Dobutamine Injection, USP, 250 mg per 20 mL in 20 mL Single-dose Fliptop Vials manufactured by Hospira Inc. Look specifically for NDC 0409-2344-02 and Lot # 27-352-DK with an expiration date of 03/15.
Brand
Hospira
Category
Drug
Based on the official FDA remedy
What to do — step by step
Stop Using Affected Vials
Do not administer any vials matching the recalled lot number or NDC to patients.
Inspect Inventory
Check all stock for NDC 0409-2344-02 and Lot # 27-352-DK with expiration 03/15.
Contact Manufacturer
Reach out to Hospira Inc. for further instructions on returning or disposing of the product.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide and Puerto Rico.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 18 months after the firm started it.
1Firm started the recall
2FDA classified it Class I
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-1540-2014 (January 10, 2014) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1540-2014 to see it in context.
Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.